Abstract: Provided is a method for treatment of liver cancer and inhibition of metastasis with CXCR4-targeted nanoparticle. A CXCR4 antagonist is used as a targeting molecule to modify a lipid carrier for the formation of nanoparticle carrying an anti-angiogenesis drug or an anti-angiogenic nucleotide. Such nanoparticle can enhance the accumulation and uptake of the drug and nucleotide in liver cancer cells as well as sensitize the liver cancer cells to treatment of said drug and nucleotide, providing a synergistic suppression of angiogenesis and tumor progression. Furthermore, the CXCR4-targeted nanoparticle can effectively inhibit metastasis of liver cancer. The pharmaceutical composition is an injectable composition; hence, is suitable for clinical application for the treatment of liver cancer.

Abstract: The present invention is related to a method for ameliorating liver fibrosis in a subject. The present invention utilizes copolymers of polyethylene glycol and poly (D, L-lactide-co-glycolide) to form nanoparticle composition containing tyrosine kinase inhibitor, such as Sorafenib. The use of nanoparticle composition is non-toxic and can increase the stability and decrease the release of drug in blood circulation. The pharmaceutical composition is in an injectable form. The nanoparticle composition containing tyrosine kinase inhibitor of the present invention can effectively ameliorate liver fibrosis including decreasing extracellular matrix accumulation, suppressing hepatic stellate cell activity, shrinking of abnormal blood vessel, and lowering microvascular density in fibrotic liver; hence is suitable for clinical application for the treatment of liver fibrosis.